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Abstract
Aim. To present the rationale, design and methodology of the GERAS project,
which examines whether assessment of frailty and mild cognitive impairment
could enhance risk prediction for biomedical, psychosocial outcomes and foster
efficient resource allocation in kidney transplantation.
Background. For the burgeoning cohort of older patients considered for kidney
transplantation, evidence gaps regarding frailty and mild cognitive impairment
limit clinical decision-making and medical management. As known risk factors
for ‘hard’ clinical outcomes in chronic illness, both require further study in
transplantation. Integrating these and other bio-psychosocial factors into a
comprehensive pre-transplant patient assessment will provide insights regarding
economic implications and may improve risk prediction.
Design. A nation-wide multi-centre prospective cohort study nested in the Swiss
Transplant Cohort Study.
Methods. Our nationally representative convenience sample includes 250 adult
kidney transplant recipients. Data sources include the Swiss Transplant Cohort Study
and primary data collected at time of transplantation, 6 months, 1 and 2 years post-
transplant via established measures (the Montreal Cognitive Assessment, Psychosocial
Questionnaire, Fried Frailty Instrument and a blood analysis), investigator-developed
instruments and datasets compiled by hospitals’ management control units, sickness
funds, the Swiss Federal Statistical Office and the European Renal Association.
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Introduction
Increasing numbers of older patients with end-stage renal
disease (ESRD) are receiving kidney transplants (Abecassis
et al. 2012, Goldstein 2012, McAdams-Demarco et al.
2013a). Even in countries where age directly limits graft
access, kidney transplantation (KTx) populations are
greying (European Renal Association – European Dialysis
and Transplant Association (ERA-EDTA), 2013, United
Network for Organ Sharing (UNOS) - Organ Procurement
and Transplantation Network (OPTN), 2014a). Older
patients’ medical needs, however, present major challenges
for the KTx healthcare agenda, as there is limited evidence
to guide clinical decision-making for organ allocation, and
pre- and posttransplant management in this cohort. There-
fore, exploring outcome-predictive factors in older KTx
patients is a rapidly rising research priority (Abecassis et al.
2012, Goldstein 2012, Singh et al. 2016). In Switzerland,
where chronological age is not a listing criterion for kidney
transplantation, over one-fifth (ca. 225%) of recipients are
aged ≥65 years at time of transplantation (Tx) (Koller et al.
2014). This gives Swiss transplant centres broad opportuni-
ties to study this older cohort’s outcomes.
Why is this study or review needed?
• Despite rising numbers of older adults being evaluated for and undergoing kidney
transplantation, there is a lack of evidence to guide risk prediction for this cohort.
• Preliminary evidence indicates that frailty and mild cognitive impairment are highly
prevalent and are independent predictors of adverse biomedical outcomes in kidney
transplantation
• The GERAS study is the first to examine frailty and mild cognitive impairment from
a comprehensive bio-psychosocial and health economic perspective. It will provide
evidence for healthcare professionals to better identify patients most at risk for
adverse outcomes. This can guide early intervention and tailor pre- and posttrans-
plant care, policy development and resource allocation, aiming to improve outcomes
for the growing cohort of elderly and frail kidney transplant recipients
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Background
Frailty as a risk prediction criterion for older KTx patients
Growing evidence suggests that, independent of chronologi-
cal age and comorbidities, frailty can guide risk prediction
in chronically ill patient groups (Makary et al. 2010, Flint
et al. 2012, Hamaker et al. 2012, Partridge et al. 2012,
Dunlay et al. 2014, Lai et al. 2014a, Jha et al. 2015,
Musso et al. 2015, Robinson et al. 2015, Singer et al.
2015). While frailty and comorbidities frequently co-exist,
they are distinct conditions with independent predictive val-
ues regarding adverse outcomes (Fried et al. 2004, Danon-
Hersch et al. 2012, Clegg et al. 2013, Chen et al. 2014).
Comorbidity is the simultaneous or sequential occurrence
and interaction of two or more disorders in the same
patient; frailty is a cumulative functional decline across
physiological systems, limiting the body’s resilience against
stressors. For example, responding to surgical procedures,
immunosuppressive medications, or infections, frail patients
experience disproportional deterioration in health status
and adverse outcomes (Fried et al. 2001, Clegg et al. 2013,
Chen et al. 2014). Preliminary findings from longitudinal
studies using the Fried Frailty Phenotype (Fried et al. 2001)
indicate that frail and pre-frail patients with ESRD and
solid organ Tx recipients have inferior clinical outcomes,
for exampl, higher rates of dialysis re-initiation, early hospi-
tal readmission and posttransplant mortality.
While KTx-specific links between frailty and such out-
comes is based on a single US patient cohort (Garonzik-
Wang et al. 2012, Roshanravan et al. 2012, Johansen et al.
2013, McAdams-Demarco et al. 2013a,b, 2015b, Exterkate
et al. 2016, Lam & Jassal 2015, Musso et al. 2015, Singer
et al. 2015, Jha et al. 2016a, Wilson et al. 2016), these
findings are extremely relevant: up to 42% and 29% of
adult haemodialysis patients are respectively pre-frail or
frail (Johansen et al. 2013, Musso et al. 2015); and respec-
tively 25% and 33% of adult KTx recipients present with
frailty or pre-frailty (Garonzik-Wang et al. 2012, McA-
dams-Demarco et al. 2013a,b, 2015b).
Importantly, as frailty also occurs in younger adults with
ESRD and accelerated metabolic ageing (Kooman et al.
2014, Musso et al. 2015), it is relevant across age groups.
In 2016, the International Society for Heart and Lung
Transplantation became the first international Tx body to
integrate frailty into its heart Tx listing criteria (Comans
et al. 2016). Still, while the American College of Surgeons
has published guidance to integrate frailty assessments into
the care of older surgical patients (Robinson et al. 2015),
no clinical practice guidelines yet exist to integrate frailty
assessment into KTx care.
Frailty in KTx: applying a bio-psychosocial perspective and
studying mild cognitive impairment (MCI)
Interplay between biomedical, psychosocial and behavioural
factors determines Tx patients’ risks regarding adverse out-
comes. Psychosocial factors also independently predict poor
posttransplant outcomes (Denhaerynck et al. 2005, Mehra
et al. 2006, Dobbels et al. 2008, Gordon et al. 2009, Pin-
sky et al. 2009, Garg et al. 2012, De Geest et al. 2013,
2014, Pascual et al. 2014). In addition, as patient-reported
outcomes, for example, health-related quality of life
(HR-QOL), are increasingly valued in KTx research (Mol-
nar-Varga et al. 2011, De Geest et al. 2013, Kumnig et al.
2014, Seiler et al. 2015), comprehensive bio-psychosocial
pre-Tx evaluations are endorsed by international Tx soci-
eties and included in KTx clinical management guidelines
(Sharing) (Mehra et al. 2006, Pascual et al. 2014).
While pre-frailty and frailty are consistently associated
with poorer HR-QOL in non-Tx populations (Kojima et al.
2016), frailty studies in Tx have thus far accounted mainly
for biomedical Tx risk factors (McAdams-Demarco et al.
2013a,b, 2015b, Singer et al. 2015). As a predictor of HR-
QOL, only one study has compared frailty with liver dis-
ease severity (Derck et al. 2015). To examine how frailty
data can improve bio-psychosocial risk prediction in KTx,
prospective pre- to post-Tx studies are essential.
Furthermore, emerging evidence links frailty with MCI, a
measurable decline in cognitive function that is excessive
relative to a patient’s chronological age and educational
background but allows basic daily life activities (Apostolo
et al. 2015) (Auyeung et al. 2011, Yassuda et al. 2012,
Kelaiditi et al. 2013, Halil et al. 2015, Jha et al. 2016a).
Up to 550% of adult ESRD patients exhibit MCI, which
independently predicts hospital readmissions and mortality
in older adults (Auyeung et al. 2011, Drame et al. 2011,
Jacobs et al. 2011, Cano et al. 2012, Yassuda et al. 2012).
Although cognitive deficits primarily improve posttrans-
plant, they may also persist (Griva et al. 2006, Van Sand-
wijk et al. 2015, Dixon et al. 2016). Recently, MCI was
linked with frailty in haemodialysis patients (McAdams-
Demarco et al. 2015c); and in end-stage heart failure,
assessing MCI alongside frailty improved mortality predic-
tion (Jha et al. 2016b). Joint examinations of frailty and
MCI in KTx are needed to clarify their interrelationships
and synergistic predictivity regarding negative outcomes.
Frailty and MCI in KTx: the need for a health economic
perspective
While dialysis and KTx are both extremely costly, KTx is
clearly more cost-effective (Ferguson et al. 2015, Sanchez-
Escuredo et al. 2015). However, as KTx demands
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significantly exceed graft availability, fair allocation
demands risk prediction models that predict both personal
and societal costs. Through reliable analyses of resources
used and health outcomes, health economic analyses can
optimize healthcare resource allocation (Wong et al. 2014,
Drummond et al. 2015, Ferguson et al. 2015, Sanchez-
Escuredo et al. 2015). As frailty is a long-term condition
with adverse patient and healthcare system outcomes, frail,
and pre-frail older non-institutionalized patients use more
healthcare resources than their non-frail counterparts (Sir-
ven & Rapp 2014, Harrison et al. 2015, Ilinca & Calcio-
lari 2015, Lyndon 2015). However, the impacts of frailty
and MCI on healthcare and societal costs and on quality-
adjusted life years (QUALYs) remains unexplored in KTx.
The GERAS study will provide essential evidence for fur-
ther studies on how frailty and MCI influence KTx costs.
Advancing frailty and MCI research in KTx by examining
the conditions’ development and aetiology
While frailty can improve, without intervention, older non-
Tx patients’ frailty commonly worsens (Clegg et al. 2013,
Apostolo et al. 2015, Goldraich et al. 2015, Harrison et al.
2015, Musso et al. 2015). Nevertheless, in KTx, the one
available study examining frailty changes indicates immedi-
ate posttransplant deterioration, with recovery to baseline
status or better after 3 months (McAdams-Demarco et al.
2015a). Longitudinal post kidney transplantation cognitive
function studies are rare. While two studies have reported
net posttransplant improvements, their results have limited
applicability to older patients, as both included relatively
young patients (Griva et al. 2006, Van Sandwijk et al.
2015). Research with extended follow-up times and across
adult KTx recipients of all ages will provide key insights
into frailty’s pre-Tx to posttransplant development.
Concomitantly, current biological frameworks of frailty
aetiology (see ‘conceptual frameworks’) suggest origins in
the dysregulation of the neuroendocrine, musculoskeletal,
metabolic and other physiological systems (Fulop et al.
2015). In older non-Tx cohorts, recent longitudinal studies
suggest the immune/inflammatory system as a key pathway
(Leng et al. 2007, 2009, Li et al. 2011, Collerton et al.
2012, Chen et al. 2014). Complex immune system alter-
ations are hypothesized to cause chronic low-grade systemic
inflammation, inducing frailty and increasing susceptibility
to chronic conditions, disabilities and mortality (Fulop
et al. 2015). Associations between frailty and certain pro-
inflammatory markers – interleukin-6 (IL-6), tumour necro-
sis factor a (TNF-a) and C-reactive protein (CRP) and
white blood cell count (WBC) – are well-documented (Leng
et al. 2007, 2009, Li et al. 2011, Collerton et al. 2012,
Chen et al. 2014, Theou & Rockwood 2015). Notably,
despite emerging aetiological pathways for MCI (Halil
et al. 2015), no reliable causal relationship has been estab-
lished (Gale et al. 2013, Fulop et al. 2015, Theou & Rock-
wood 2015). With only one related study in Tx recipients
(Singer et al. 2015), inflammation markers’ pre-Tx to post-
transplant evolution and their interrelationships with frailty
and MCI in KTx offer high research potential (De Martinis
et al. 2006, Li et al. 2011, Gale et al. 2013, Fulop et al.
2015, Hubbard & Jatoi 2015).
The study
Aims
The GERAS study’s primary aims are: (1.1) to examine
whether pre-Tx frailty and MCI predict patient’s survival
and HR-QOL posttransplant (primary outcome) and graft
survival and acute rejection episodes (secondary outcomes);
(1.2) to explore whether pre-Tx frailty and MCI predict
healthcare and societal costs of KTx; and (1.3) to assess
and compare posttransplant QUALYs of KTx recipients
who are non-frail, pre-frail/frail and pre-frail/frail with
MCI. Our initial hypothesis is that pre-Tx frailty and MCI
can have a negative impact on these primary and secondary
outcomes.
The project’s secondary aims are: (2.1) to examine the
prevalence, evolution and interrelationships of frailty and
MCI for 2 years posttransplant; (2.2) to examine the levels
of selected inflammatory biomarkers (CRP, total WBC,
TNF-a and IL-6) in relationship with frailty status and
MCI; and (2.3) to explore whether pre-Tx levels of the
selected biomarkers predict changes in frailty status and
cognitive function.
Methodology
Conceptual frameworks
The GERAS study employs four conceptual frameworks: (1)
The Fried Frailty Phenotype is an internationally applied, psy-
chometrically validated conceptual model of frailty. Based on
indicators of physical fitness and metabolism, it measures
weakness, slowness, low levels of physical activity, lower total
energy expenditure and chronic undernutrition. Depending
on the number of indicators present, patients are classed as:
non-frail (score 0); pre-frail (score 1-2); or frail (score ≥3)
(Fried et al. 2001, 2004, Cesari et al. 2014, Walston & Ban-
deen-Roche 2015). This is predominantly applied in end-stage
organ failure to predict risks of adverse outcomes independent
of chronological age, comorbidities and disabilities. Its 10-
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minute administration time suits it to routine clinical applica-
tion (Exterkate et al. 2016). (2) The STCS-developed
Expanded Biopsychosocial Framework for Transplant
Research (described by De Geest et al. 2013) provides bio-
psychosocial perspective to select outcomes and con-
founders. (3) Chen et al.’s (2014) conceptual model will
guide explorations of the interrelationships between frailty
and MCI and (4) Halil et al.’s (2015) model highlights
chronic low-grade systemic inflammation’s aetiological role
in both conditions.
Study design, setting
GERAS is a multi-centre prospective cohort study across five
Swiss KTx centres. It is nested in the STCS, a long-term open
prospective cohort study that has enrolled over 95% of KTx
recipients in Switzerland since 2008. More information on
the STCS is described elsewhere (Koller et al. 2013). Assess-
ing patients immediately pre-Tx, with follow-up at
6 months, 1 and 2 years post-Tx, the GERAS study began in
January 2015 and will extend until June 2020. Figure 1 illus-
trates the study design, data sources and variables.
Study team and cooperation partners
This study is integrated in a research programme on ageing
and frailty in KTx. Coordinated via the University of
Basel’s Institute of Nursing Science (INS), it represents a
collaboration between five Swiss KTx centres, Johns Hop-
kins University (US), University of Pittsburgh (US) and the
University of Lugano (Switzerland). Cooperation partners
include the STCS, all participating hospitals’ laboratories
and management control units, the University Hospital
Basel Clinical Trial Unit, Santesuisse and the Swiss Kran-
kenkasse (healthcare fund).
Sample selection and size
A consecutive recruited convenience sample of adult
deceased- and living-donor KTx recipients (aged ≥20 years)
who are enrolled in the STCS is included, unless they are
multiple organ Tx recipients, are incapable of informed
consent (IC), have insufficient knowledge of English,
French, German or Italian, or have severe functional
impairments which could influence the cognitive tests. A
power analysis for patient and graft survival (aim 1.1) indi-
cated a minimum sample size of 250 patients for detection
of proportional differences within reported ranges in both
outcomes according to frailty status at KTx [5-year post-Tx
patient survival: 775% for frail vs. 915% for non-frail
patients, based on pre-KTx frailty prevalence (251% frail,
749% non-frail)], with 80% power and a two-sided alpha
level of 005 (Garonzik-Wang et al. 2012, McAdams-
Demarco et al. 2015b). Study enrolment began in February
2016 and will continue for approximately 25 months,
guided by the yearly number of adult KTx in Switzerland
(n = 296, data 2014) (SwissTransplant 2014) and 15%
non-eligibility, 15% non-participation and 30% attrition.
Data sources, variables and measurements
Data sources include: (1) STCS datasets; (2) primary patient
data collection via established or investigator-developed
interview questionnaire (Table 1); and (3) other data
sources (medical charts, hospitals’ management control
records, the Swiss healthcare fund, the Swiss Federal Statis-
tical Office and the European Renal Association).
All GERAS study documents are available in English,
French, German and Italian. They were developed via itera-
tive processes with multiple review rounds by researchers.
Culturally sensitive professional translations were per-
formed. Thereafter, native-speaking research team members
and nursing researchers reviewed translation accuracy, item
comprehensibility and data availability at KTx centres.
Using a convenience sample of haemodialysis patients, KTx
candidates and KTx recipients, the procedures and instru-
ments were pilot tested in three centres. Variables and mea-
surements are described in detail below.
Primary variables of interest
Frailty is assessed pre-Tx, at 6 months, 1 year and 2 years
posttransplant, using an adapted Fried Frailty Instrument
(Table 2; Jha et al. 2016a). Originally developed and psy-
chometrically tested in the US Cardiac Health Study (Fried
et al. 2001), then modified for Tx patients, both the origi-
nal and modified versions have good construct and predic-
tive validity across chronically ill cohorts. In end-
stage organ failure and Tx, it has predictive validity for
biomedical outcomes in middle-aged and older adults
(Garonzik-Wang et al. 2012, Hamaker et al. 2012,
McAdams-Demarco et al. 2013b, 2015a,b, Lai et al.
2014b, Buta et al. 2015, Handforth et al. 2015, Theou
et al. 2015). The modified version requires ten minutes to
evaluate five domains: ‘weakness’ (measured hand grip
strength), ‘slowness’ (measured habitual walking speed), ‘a
low level of physical activity’ (one self-report item), ‘a lower
total energy expenditure’ (one self-report item on subjective
exhaustion) and ‘chronic undernutrition’ (one self-report
item on loss of appetite). Given that pre- to posttransplant
weight assessments often reflect fluctuating fluid levels,
self-reported loss of appetite was used to measure chronic
undernutrition. Summary scores indicate non-frailty (score
0), pre-frailty (score 1-2) or frailty (score 3-5) (Table 2) (Jha
et al. 2016a).
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MCI is assessed via the Montreal Cognitive Assessment
(MoCA) pre-Tx, then at 6 months, 1 year and 2 years
post-Tx. This 10-minute assessment covers visiospatial and
executive functioning, naming, memory, attention, lan-
guage, abstraction, delayed recall and orientation (Nasred-
dine et al. 2005, Tiffin-Richards et al. 2014, Apostolo et al.
2015, Cecato et al. 2016, Julayanont et al. 2015). Regard-
ing MCI detection in older community-dwelling adults and
haemodialysis patients, the MoCA’s sensitivity and speci-
ficity exceed those of the Mini Mental State Examination
(gold standard). Possible scores range from 0-30; scores
<26 indicate MCI. To avoid recall bias for certain items
(e.g. general vocabulary, animal names, calculations), a dif-
ferent version is used for each measurement point (Nasred-
dine et al. 2005, Tiffin-Richards et al. 2014, Julayanont
et al. 2015).
Inflammatory biomarkers: total WBC (in 109/L) and CRP
(in milligrams per litre) are determined for venous blood
samples (serum and ethylenediamine tetra-acetic acid sam-
ple) pre-Tx, then at 1 and 2 years post-Tx. As levels of
TNF-a and IL-6 are not monitored in the STCS, measure-
ments (in picograms per millilitre) are based on serum
Primary outcomes (aim 1·1) Health economic outcomes (aim 1·2)
Secondary outcomes (aim 1·1)
Primary vaiables of interest
Tx
Sample characteristics, confounders and baseline value of outcomes
Data sources
Socio-demographic and psychosocial domain (pre-Tx) (aim 1·1, 1·2, 2·3)
Behavioral domain (pre-Tx) (aim 1·1, 2·3)
Comorbidities (pre-Tx) (aim 1·1, 2·3)
Baseline value of outcome (pre-Tx) (aim 1·1)
Biomedical domain (pre-Tx) (aim 1·1, 1·2, 2·3)
Legend
Patient survival QUALYs: calculated based on
EQ-5D-5L (all 4 time points)
Data on patient survival (6 months, 1 and 2 years post-Tx)
Expected remaining lifetimes (at time of KTx)
Healthcare and sociatal costs: calculated based on
SwissDRG cost weights according to minimum dataset, base rate applied at each KTx center for in-hospital care (hospital discharge)
Claims data for outpatient procedures/visits and medication use post-Tx (post-Tx)
Official statistics on gross income from employment
Frailty - Fried Frailty Phenotype: (all 4 time points) (all aims)
Mild cognitive impairment - MoCa© (all 4 time points) (all aims)
Inflammatory markers - WBC, CRP, TNF-α, IL-6 (pre-Tx, 1 and 2 years post-Tx) (aim 2·2, 2·3)
Educational level, marital status, household income (Swiss Health Survey)
Depressive symptomatology (subscale HADS©)
Stress (1 item, as in Elo et al. 2003)
Patient’s chronological age, sex Swiss Transplant Cohort Study
Primary data collection as part of the GERAS study
Hospitals’ management control units
Sickness funds
Swiss Federal Statistical Office
European Renal Association - European Dialysis and Transplant Association
Smoking (Swiss HIV Cohort Study)
Adherence to co-medications (adapted version of BAASIS©)
BAASIS©: Basel Assessment of Adherence to Immunosuppresive Medication Scale
HADS©: Hospital Anxiety and Depression Scale
HLA: Human Leukocyte Antigen
HR-QOL: Health-related Quality of Life
ICD: International statistical Classification of Diseases and related health problems
IL-6: Interleukin 6
MoCa: Montreal Cognitive Assessment
QUALY: quality adjusted life years
STCS: Swiss Transplant Cohort Study
SwissDRG: Swiss Diagnosis Related Groups
TNF-α: Tumor necrosis factor α
VAS: Visual Analogue Scale
WBC: White blood cell count
SwissDRGs minimum dataset: patient age and sex, length of stay (in days), secondary diagnoses (ICD-10 classification),
surgical procedures (CHOP classification), comorbidities and/or complications severity, patient clinical complexity level
CHOP: la Classification suisse des interventions chirurgicales
CRP: C-reactive protein
Charison Comorbidity Index
HR-QOL (VAS scale)
Type of immunosuppresive regimen
Total number of HLA mismatches
Ischemic time of donor organ
Donor chronological age and sex
Type of donor
Extended criteria donation
Structured self-report questionnaire for informal care and productivity losses (6 months, 1 and 2 years post-Tx)
Graft survival
Acute rejections (Banff classification)
All assessed at 6 months, 1 and 2 years post-Tx
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Figure 1 Flow chart of the GERAS study design, data sources and variables.
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Table 1 Investigator-developed questionnaire on informal care and productivity losses.
Construct Instructions and question Variable type and values
General information Please fill out this general information before
conducting the interview:
a. Day of the interview
b. Who was interviewed?
c. Who conducted the interview?
a. Open-ended: Day/Month/Year
b. Categorical: The patient / An informal caregiver of the
patient / The patient and caregiver were interviewed
together
c. Open-ended: name and surname
Living arrangements
of the patient
Where does the patient currently live? Categorical: At home alone / At home with other people /
In a healthcare or social organization (please indicate the
name of the organization, and unit/ward – if applicable)
/ Other, please specify
Changes to the
working condition
of the patient
In the last 6 months / 1 year, did the patient have
to change her/his working condition because of
her/his kidney transplantation?
Categorical: No / She/he had to quit her/his job / She/he
had to reduce the frequency of her/his occupation
(please specify the reduction in %) / She/he lost working
days (please specify how many days) / Other, please
specify:
Homecare received In the last 6 months / 1 year, did the patient and/
or her/his relatives pay for homecare assistance
because of the kidney transplantation?
Table indicating the following types of homecare
assistance: domestic worker / companion /
physiotherapist / nurse / other (please specify). For each,
the interviewer indicates:
a. Open-ended: Frequency with which the homecare
assistance was received
b. Open-ended: Total estimated expenditure by the
patient and/or her/his relatives
Presence of and
information on the
patient’s informal
caregiver
a. Does the patient have a person who assists her/
him in daily life, but is not paid for doing so
(informal caregiver)? (Note: if the patient has
more than one informal caregiver, please fill out
this question for the person who assists her/him
most frequently)
b. What is the age of the informal caregiver?
c. What is the sex of the informal caregiver?
d. What is the working condition of the informal
caregiver?
e. If she/he is employed, please specify his/her
function
a. Dichotomous: Yes / No (please stop the interview)
b. Open-ended: years
c. Dichotomous: Male / Female
d. Categorical: Employed / Student / Housewife or – man
/ Retired / Unemployed
e. Categorical: No management function / Top, upper or
middle level management function / Lower management
function / Other (please specify)
Presence of and
information on the
patient’s informal
caregiver (cont.)
a. Please specify the highest educational degree
completed by the informal caregiver:
b. What is the relationship of the informal
caregiver with the patient?
a. Categorical: No completed school or professional
education (less than 9 formation years) / Mandatory
school (primary/secondary/junior high/district school) (9
formation years) / Apprenticeship or full-time vocational
school (10-13 formation years) / Diploma qualifying for
university admission (Matura) (13 formation years) /
Higher professional education (e.g. master craftsman
diploma, federal diploma) (14-16 formation years) /
Higher technical or commercial school (e.g. school for
social work, school for engineering) (14-18 formation
years) / University degree (e.g. bachelor or master of
science) (16 or more formation years) / Other education
(open-ended question) / I do not want to answer
b. Categorical: Spouse or partner / Son or daughter /
Other family member (please specify) / Friend / Other
(please specify)
Type of assistance
provided by the
informal caregiver
In the last 6 months / 1 year, which type(s) of
assistance did the informal caregiver provide to
the patient, and how much time did she/he
dedicate for doing so?
Open-ended: table indicating ‘type of assistance’ and
‘number of hours per day’
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samples collected during the GERAS study. Each KTx cen-
tre’s laboratory performs pre-analytical procedures accord-
ing to study-specific standard operating procedures. The
University Hospital Basel’s Department of Laboratory Medi-
cine coordinates shipping and analysis of the serum samples.
Primary, secondary and health economic outcomes
Primary outcomes for aim 1.1 are patient survival and HR-
QOL; secondary outcomes are graft survival and acute
rejection episodes. Health economic outcomes for aim 1.2
are QUALYs and health care and societal costs of KTx.
Table 3 provides detailed information on all outcomes.
Socio-demographic variables
Three items are assessed pre-Tx using the STCS Psychosocial
Questionnaire: educational level (categorical, nine answer cat-
egories), marital status (categorical, four answer options) and
household income (categorical, five answer options). As noted
above, the STCS self-report questionnaire consists of
psychometrically tested items (De Geest et al. 2013, 2014).
Patients’ chronological age (continuous, in years) and sex
(male / female) are retrieved via medical chart review.
Psychological and behavioural variables
Four psychosocial variables are assessed pre-Tx using
the STCS Psychosocial Questionnaire: depressive
symptomatology [Hospital Anxiety and Depression Scale-7
item depression subscale (Zigmond, 1983)], stress [cate-
gorical, five response options as in occupational research
(Elo et al. 2003)], smoking (categorical, five answer
options, from the Swiss HIV Cohort Study) and adher-
ence to medications [two items on taking adherence and
drug holidays from an adapted version of the Basel
Assessment of Adherence to Immunosuppressive Medica-
tions Scale (BAASIS©)] (Glass et al. 2006, 2008,
Deschamps et al. 2008, Ducci et al. 2013, Marsicano Ede
et al. 2013).
Biomedical variables
Five variables are extracted from STCS data: immunosup-
pressive regimen type (Azathioprine, Cyclosporin, EC-
Mycophenolic acid, Everolimus, Glucocorticoid, Mycophe-
nolat mofetil, Sirolimus, Tacrolimus, induction therapy),
total number of HLA mismatches (count), cold ischaemic
time of donor organ (minutes), donor and recipient
chronological ages (years), donor and recipient sexes
(male /female), donor type (post-brain death (DBD), post-
circulatory death (DCD), living-related or living-unrelated),
extended-criteria donor (yes /no). Information on the STCS
data has previously been elaborated (Koller et al. 2013, De
Geest et al. 2014). Based on medical chart review at KTx,
the total number of comorbidities is assessed via a Charlson
Table 1 (Continued).
Construct Instructions and question Variable type and values
Changes in the
working condition
of the informal
caregiver
In the last 6 months / 1 year, did the informal
caregiver have to change her/his working
condition to assist the patient?
See item ‘Changes to the working condition of the
patient’
Financial support
for informal
caregiving
Does the informal caregiver receive financial
support for assisting the patient?
Dichotomous: No / Yes (please specify the type and
amount of financial support received)
Assistance provided
to the patient by
other people
a. In the last 6 months / 1 year, have there been
other people who assisted the patient, although
with less intensity than the caregiver?
b. If yes, please fill out the following table
a. Dichotomous: No / Yes
b. Open-ended: table indicating ‘relationship with the
patient’ and ‘number of hours per week’
Transportation
expenditures for
patient assistance
incurred by the
patient or the
caregiver
a. In the last 6 months / 1 year, did the patient or
the caregiver bear the burden of transportation
expenditures for patient assistance?
b. If yes, please fill out the following table,
indicating information for a one-way trip (not a
round-trip).
a. Dichotomous: No / Yes
b. Open-ended: table indicating ‘distance (km)’,
‘transportation means’, ‘estimated expenditure’ and
‘number of times’
Other expenditures
for patient
assistance incurred
by the patient or
the caregiver
a. In the last 6 months / 1 year, did the patient or
the caregiver bear the burden of other
expenditures for patient assistance?
b. If yes, please fill out the following table,
indicating the type, estimated cost and frequency
of each expenditure.
a. Dichotomous: No / Yes
b. Open-ended: table indicating ‘type of expenditure’,
‘estimated expenditure’ and ‘number of times’
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Comorbidity Index version adapted for KTx (Hemmelgarn
et al. 2003). HR-QOL (VAS scale) will be measured pre-Tx
to control for its baseline value.
Patient recruitment and data collection
Coordinated and led by the INS, patient recruitment and
data collection involve four phases:
• Training of data collectors, including research team
members, KTx centre nursing and medical staff and
nursing science students. All are trained in their native
language through personalized sessions at KTx centres.
Moreover, each receives a step-by-step data collection
manual and podcast and can contact GERAS team
members if required.
• Patient recruitment: on patients’ hospital admission for
KTx, data collectors assess their eligibility and fulfil
informed consent (IC) requirements for living- and
deceased-donor grafts.
• Data collection: data collection packages are pre-
pared at the INS and the coordinating laboratory.
Patients’ primary data are collected as follows:
(1) patient data coding form, (2) Fried Frailty
Instrument, (3) MoCA, (4) STCS Psychosocial Ques-
tionnaire, (5) venous blood sampling, (6) investiga-
tor-developed interview questionnaire on informal
care received and productivity losses. Thereafter, the
Charlson Comorbidity Index is scored based on med-
ical chart review. Patient data collection booklets are
stored in sealed envelopes and blood samples sent to
participating laboratories according to centre-specific
procedures.
• Return of completed data collection booklets: after
storage in locked cabinets at the KTx centres,
Table 2 Fried Frailty Instrument as adapted for Tx patients (Fried et al. 2001).
Domain Assessment and scoring
Weakness Assessment: Grip strength as measured by the hand-held Jamar dynamometer (Sammons Preston Inc.,
Boiling Brook, IL), which has established test–retest, inter- and intra-rater reliability (Roberts et al.
2011).
• Standardized assessment protocol from the American Society of Hand Therapy, as adapted by
Roberts et al. (2011).
• Mean values of three consecutive tests of maximum grip strength with the left and right hand are
calculated. Grip strength is considered weak if this mean value is ≤ two standard deviations of
sex- and age-adjusted normative values (Mathiowetz et al. 1985).
• Hand dominance, and the location of a dialysis shunt are recorded.
Scoring: 1 point if weakness is present.
Slowness Assessment: Time in seconds to complete a 5 m walk at the patient’s habitual pace is tested, measured
following a standardized protocol. Walking speed is considered slow if the average of three attempts
takes ≥6 seconds.
Scoring: 1 point if slowness is present.
Low level of physical activity Assessment: through 1 closed-ended question: ‘How often do you engage in activities that require a
low or moderate level of energy, such as gardening, cleaning the car or going for a walk? (Answer
options: more than once a week / once a week / one to three times a month / hardly ever, or never).
A response of ‘one to three times a month’ or ‘hardly ever, or never’ is classified as a low level of
physical activity.
Scoring: 1 point if a low level of physical activity is present.
Exhaustion Assessment: through 2 closed-ended questions: ‘In the last week, did you feel on at least three days,
that everything you did was an effort?’ and ‘In the last week, did you feel on at least three days, that
you could not get going?’ (Answer option for each question: yes / no). A response of ‘yes’ to either
one or both questions is considered as exhaustion.
Scoring: 1 point if exhaustion is present.
Loss of appetite* Assessment: through 1 closed-ended question: ‘Have you, in the last three months, been eating more/
less than usual?’ (Answer options: less / unchanged / more). A response of ‘less’ is classified as
chronic undernutrition.
Scoring: 1 point if chronic undernutrition is present.
Overall score Non-frail: 0, Pre-frail: 1-2, Frail: 3-5
*The adaptation for Tx patients considers the item loss of appetite, which is questioned instead of unintentional weight loss. The latter is
unreliable in Tx populations given potential fluid overload.
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completed booklets are collected bi-monthly by
research team members and confidentially stored at the
INS data management centre. Prior to analysis, data
quality (e.g. completeness) is verified.
Data management and analysis
In collaboration with the University Hospital Basel Clinical
Trial Unit, a secure web-based data platform (SecuTrial)
is used to ensure comprehensive structured patient follow-
up and to enter, manage, link and code data from all
sources (SecuTrial, 2000). Initially, missing data, data dis-
tributions and violations of assumptions underlying applied
statistical techniques are checked and handled as
appropriate. All analyses employ STATA (StataCorp LP,
College Station, TX, USA) and SAS (SAS Institute AG, Wal-
lisellen, Switzerland) statistical software, applying a two-
tailed significance level (a) of .05. Data analyses are per-
formed as follows:
Aim 1.1: Patient survival (primary outcome) and graft
survival (secondary outcome) require a competing risks
analysis to account for simultaneous risks of mortality and
graft loss in KTx (Pintilie 2007, Bakoyannis & Touloumi
2012, Koller et al. 2012, Wolbers et al. 2014, Geskus
2015). Standard analysis for this type of data results in
overestimated outcome probabilities (Bakoyannis & Tou-
loumi 2012, Wolbers et al. 2014, Fonseca et al. 2015, Ges-
kus 2015). For both outcomes the cause-specific hazard
Table 3 Overview of primary, secondary and health economic outcomes.
Outcome
Variable type and values
Time point(s) Data source, measurement and psychometrics (if applicable)
Patient survival (Primary
outcome)
Dichotomous (yes / no) & time-
to-event.
6 months, 1 and 2 years post-Tx.
STCS dataset: registered by two independent physicians. STCS
Endpoint Committee ascertains registered deaths (Koller et al.
2013).
HR-QOL (Primary
outcome)
Continuous (range 0-100).
6 months, 1 and 2 years post-Tx.
STCS dataset: VAS. Psychometric properties in oncology patients
are reported in (de Boer et al. 2004).
Graft survival
(Secondary outcome)
Dichotomous (yes / no) & time-
to-event.
6 months, 1 and 2 years post-Tx.
STCS dataset: STCS classification developed by clinical experts
(Koller et al. 2013).
Acute rejection (Secondary
outcome)
Dichotomous (yes / no).
6 months, 1 and 2 years post-Tx.
STCS dataset: measured according to the Banff classification system
(Wu et al. 2014, Wu et al. 2015).
Healthcare and societal
costs (Health economic
outcome)
Continuous, dichotomous &
categorical.
Pre-Tx, data reflecting time of
hospital discharge, at 6 months,
1 and 2 years post-Tx.
Calculated based on:
• Management control unit of KTx centres: SwissDRG cost
weights associated to each patient case (in-hospital care) based
on minimum dataset; base rate applied in each KTx centre
(SwissDRG AG 2016).
• Sickness funds [recruited through Santesuisse (Santesuisse,
2016)]: claims data for each outpatient procedure/visit per-
formed or medication used (posttransplant).
• Structured self-report questionnaire filled out by patients and/or
their primary informal caregiver: informal care and productiv-
ity losses (see table 6).
• Swiss Federal Statistical Office: Official statistics on gross
income from employment to calculate cost of time (Swiss Fed-
eral Statistical Office 2014).
Quality-adjusted life years
(QUALYs) (Health
economic outcome)
Categorical, 5-point Likert scale.
Pre-Tx, at 6 months, 1 and
2 years post-Tx.
Dichotomous (yes / no) & time-
to-event.
6 months, 1 and 2 years post-Tx.
Continuous.
At time of Tx.
Calculated based on:
• Primary data collection with STCS Psychosocial questionnaire
(pre-Tx, see 2.3.3.3); STCS dataset (posttransplant): EuroQol-
5D-5L instrument (Drummond et al. 2015, EuroQol 2016).
• STCS dataset: data on patient survival (see supra).
• European Renal Association – European Dialysis and Trans-
plant Association Registry: Annual Report for expected remain-
ing lifetimes at time of KTx [European Renal Association –
European Dialysis and Transplant Association (ERA-EDTA),
2013].
KTx, kidney transplantation; Pre-Tx, pre-transplant; Post-Tx, post-transplant; STCS, Swiss Transplant Cohort Study; SwissDRG, Swiss
Diagnosis Related Groups; Tx, transplantation; VAS, Visual Analogue Scale.
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(CSH) and cumulative incidence functions (CIF) are dis-
played and a multivariate regression performed. Using
frailty and MCI as independent variables of interest, socio-
demographic, biomedical, psychosocial and behavioural
variables are screened as potential confounders. Regression
on the CSH consists of a Cox cause-specific proportional
hazards model, regression on the CIF of a Fine and Gray
model (Lee et al. 2012, Wolbers et al. 2014, Geskus 2015).
Aim 1.2: Regarding HR-QOL (primary outcome) and
acute rejection episodes (secondary outcome), multivariate
mixed effects logistic and linear regression models are
applied to flexibly account for the multi-level clustered lon-
gitudinal data structure and missing data. In all models,
patients are added as a random effect, with length of fol-
low-up, frailty and MCI considered as fixed effects. Socio-
demographic, biomedical, psychosocial and behavioural
variables are tested as confounders. The necessity of includ-
ing polynomials to model a non-linear relationship with
HR-QOL is explored. In all models for aim 1.1, interaction
between frailty and MCI is tested to explore a potential
cumulative effect on outcomes. Also, the use of variable- or
patient-clustering techniques is explored to summarize
information on correlated variables. Model building applies
a block-entry method.
Aim 1.3: For health economic outcomes, a discount rate
of 3% is applied to both costs and QUALYs (Gold et al.
1996, Tan-Torres Edejer et al. 2003). Up to 2 years post-
transplant, health care and societal costs and QUALYs are
described via appropriate descriptive measures of central
tendency and dispersion. Comparison of healthcare and
societal costs, and QUALYs are performed for the three
clinically relevant subgroups: non-frail vs. pre-frail/frail vs.
pre-frail/frail with MCI. Graphic representations are
applied for data visualization. A mixed effects log-linear
regression model is applied for the continuous outcome
variable of healthcare and societal costs, where patients are
added as a random effect. Follow-up length, frailty, MCI
and the interaction of the latter two conditions are consid-
ered fixed effects. Socio-demographic, biomedical and psy-
chosocial variables are tested as confounders.
Aim 2.1: Prevalence, evolution and interrelationships
between frailty and MCI are analysed descriptively from
pre-Tx to 2 years posttransplant. Graphic methods are
applied for data visualization. Changes over time are tested
using mixed effects regression modelling, with frailty and
MCI employed as mutual predictors to test for interrela-
tionships between the two.
Aim 2.2: Descriptive statistics of central tendency and
variability are applied to describe the levels of the selected
inflammation markers (CRP, total WBC, TNF-a and IL-6)
in relation to frailty status (non-frail, pre-frail or frail) and
cognitive function (MCI, no MCI). Graphics are applied for
data visualization. Associations between inflammatory
markers, frailty and MCI are tested using a mixed effects
(ordinal) logistic regression analysis, with frailty status
(non-frail, pre-frail, frail) and MCI (yes/no) as outcome
variables. Since inflammatory markers may be correlated,
we explore the use of variable- or patient-clustering tech-
niques.
Aim 2.3: The aetiological values of pre-Tx inflammatory
markers regarding post-Tx changes in frailty status (non-
frail, pre-frail, frail) are examined using mixed effects logis-
tic regression models, entering patients as a random effect
and follow-up time and inflammatory markers as fixed
effects. To explore possible delayed effects of inflammatory
marker information on frailty, we lag frailty status. Con-
founders and model building techniques are similar to those
used for aim 1.1’s mixed-effects models.
Regarding handling of missing data and sensitivity analy-
ses, for all analyses, missing data’s biasing effects are
mapped and their influence on the modelling results
explored using sensitivity analyses under various scenarios.
For example, health economic evaluation (aim 1.2), sensi-
tivity analyses use varying discount rates (00%, 50% and
60%) (Gold et al. 1996, Tan-Torres Edejer et al. 2003).
Ethical considerations
The STCS received ethical approval prior to data collection;
its IC includes approval for further use of data in STCS
approved studies such as this (De Geest et al. 2013, Koller
et al. 2013). The GERAS study received ethical approval
from all responsible ethical committees (Ref. Nr. EKNZ
2015-235). Participants will be provided with verbal and
written information about the study. A written informed
consent is obtained prior to participating in the study. Par-
ticipation is voluntary and may be discontinued at any time
without implications for patient treatment. We comply with
all national and international guidelines and privacy laws
concerning treatment of patients in clinical studies.
The GERAS study consortium
Patient and provider involvement is organized through an
advisory body. Active partnerships are pursued between the
research team, KTx patients, the Swiss Kidney Patient Asso-
ciation, KTx nursing, medical and allied health profession-
als, regional and national governing bodies and policy
makers. Integrating these members’ diverse perspectives will
improve the study’s quality, relevance and effectiveness
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regarding researcher conduct and management, analysis,
interpretation and dissemination of findings and monitoring
and evaluation of the study process. Patient and provider
involvement is also essential for successful implementation
of our findings in KTx clinical practice and policy develop-
ment and identification and prioritization of areas for fur-
ther research (Involve Network and National Institute for
Health Research, 2012, National Institute for Health
Research and Research Design Service London, 2013).
Validity and reliability/Rigour
Several steps ensure the GERAS study’s validity, reliability
and rigour. Nesting the study in the rigourous longitudinal
STCS data structure and the application of SecuTrial for
patient follow-up minimizes study drop-out and ultimate
selection bias. Across all KTx centres, consistent use of
methodologies proven in US and Australian studies on
frailty and MCI (Jha et al. 2015, 2016a) ensures national
and international comparability of results. Furthermore, all
instruments have been tested for reliability and validity in
previous studies including Tx populations. When the entire
data collection procedure was pre-tested at three participat-
ing KTx centres, only minor adaptations were necessary.
To check data quality, 5% of data booklets will be ran-
domly tested, that is, two research team members will inde-
pendently enter their contents for analysis.
Discussion
Clinical, scientific and policy impact
Accumulating evidence on the high prevalence and indepen-
dent predictive values of frailty and MCI regarding inferior
clinical outcomes features both as critical issues for solid
organ Tx candidates and recipients. Only recently recog-
nized in Tx, neither condition is fully considered in guideli-
nes for Tx policy, patient assessment nor direct practice
pathways. For the rapidly growing group of older Tx
patients, GERAS findings on frailty and MCI will likely
guide and optimize clinical management. This is particu-
larly relevant in Swiss settings, where no upper age limit is
applied to Tx candidacy. As the largest solid organ Tx
group, KTx patients receive approximately 296 grafts in
Switzerland yearly, each costing Swiss society between
60,000-100,000 Swiss Francs (Federal Office of Public
Health, 2012). Thus, the GERAS study is addressing a sig-
nificant challenge. Moving beyond previous biomedical-
focused frailty research, it jointly examines frailty and MCI
from bio-psychosocial and health economic perspectives.
This study will continue to drive improvements in care
quality and appropriateness and of policy development for
ageing and frail KTx cohort as follows:
• Through its comprehensive perspective, the GERAS
study will significantly enhance risk prediction regard-
ing adverse outcomes in KTx. Integrating its findings in
clinical practice guidelines and training programs will
guide modifications in the complex care of pre-frail
and frail patients. In addition to enhancing therapeutic
decision-making concerning transplant candidacy, it
may even accelerate and improve posttransplant reha-
bilitation and related outcomes (e.g. via enhanced phys-
ical therapy, exercise and nutrition). As such an
approach is patient-centred, nurses will be key partici-
pants, helping optimize chronic illness and symptom
management while providing evidence-based psychoso-
cial support.
• Nested in the STCS, studying a nationally representa-
tive cohort of KTx patients including older recipients,
GERAS enables rigourous study of the clinical, psy-
chosocial and health economic consequences of kidney
Tx in frail and/or cognitively impaired patients.
• Given the expansion of Tx eligibility to older and more
vulnerable patients, it is imperative to understand the
impact of frailty and MCI on KTx’s cost-effectiveness.
Considering patient, healthcare system and societal per-
spectives, GERAS will identify the risks of transplant-
ing frail and/or MCI patients. At the policy level, it
will provide essential evidence about the optimal use of
limited resources to maximize health outcomes in
adults with ESRD.
• Investigating inflammatory biomarkers in KTx will pro-
vide preliminary insights into the relevance of chronic
low-grade systemic inflammation as a pathway to
frailty and MCI. By exploring these biomarkers’ values,
GERAS will notably contribute to scientific advance-
ments in pre-KTx screening for frailty and MCI. Sup-
porting diagnosis of both will facilitate tracking their
development and assist healthcare professionals in clini-
cal and therapeutic decision-making.
Strengths and limitations
The GERAS project has three key strengths. First, its multi-
centre design and nationally representative cohort consider-
ably expand current evidence on frailty and MCI in KTx,
with generalizable results. Second, by jointly examining
frailty and MCI from a comprehensive bio-psychosocial
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and health economic perspective, it significantly broadens
the existing–primarily clinical–research focus. Third, com-
peting risks analysis is a pioneering methodology: despite
the frequent occurrence of competing outcomes, the use of
this statistical technique in Tx is still in its infancy (Huang
et al. 2014, Aubert et al. 2015, Fonseca et al. 2015, Sapir-
Pichhadze et al. 2016).
Conversely, certain limitations should be considered
when interpreting our findings. Balanced against our power
analysis’s required sample size, the rather small number of
KTx performed annually in Switzerland precludes a ran-
domized sampling strategy to enhance generalization.
Finally, Switzerland’s small population, linguistic diversity,
variability across care systems and KTx centres and hetero-
geneous clinical profiles of KTx donors and recipients might
diffuse the impact of frailty and MCI on outcomes.
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